Li Ya-Ping, Cai Jie-Wen, Liao Li-Juan, Ding Han, Cao Xun-Jie, Zhu Guo-Dong, Guo Xu-Guang
Department of Clinical Laboratory Medicine, The Third Affiliated Hospital of Guangzhou Medical University, China.
Department of Clinical Medicine, The Second Clinical School of Guangzhou Medical University, China.
Jpn J Infect Dis. 2022 May 24;75(3):302-308. doi: 10.7883/yoken.JJID.2021.406. Epub 2021 Nov 30.
Based on previous studies, we found that Bacillus Calmette-Guérin (BCG) vaccination may play a role in preventing SARS-CoV-2 infection. Therefore, we conducted a meta-analysis to investigate this protective effect. We searched the Embase, PubMed, Web of Science, Cochrane Library, BioRxiv, and MedRxiv databases for studies that evaluated the relationship between BCG vaccination and SARS-CoV-2 infection or COVID-19 disease. The quality of all included studies was assessed using the Risk of Bias in Non-randomized Studies of Interventions and the Agency for Healthcare Research and Quality data tools. Review Manager (Version 5.3) was used to conduct all the data analyses. A total of eight studies were ultimately included in our meta-analysis. Our primary analysis found a significantly lower SARS-CoV-2 infection rate in the BCG vaccination group compared to the control group, with an odds ratio of 0.61, (95% confidence interval 0.39 to 0.95, P = 0.03; I = 31%, and P = 0.21, respectively). Our study indicates that BCG vaccination can protect against SARS-CoV-2 infection. However, there is insufficient evidence that BCG vaccination can reduce the severity of COVID-19.
基于先前的研究,我们发现卡介苗(BCG)接种可能在预防新型冠状病毒2(SARS-CoV-2)感染中发挥作用。因此,我们进行了一项荟萃分析来研究这种保护作用。我们在Embase、PubMed、Web of Science、Cochrane图书馆、BioRxiv和MedRxiv数据库中检索了评估卡介苗接种与SARS-CoV-2感染或冠状病毒病2019(COVID-19)之间关系的研究。使用干预非随机研究中的偏倚风险和医疗保健研究与质量机构的数据工具对所有纳入研究的质量进行评估。使用Review Manager(版本5.3)进行所有数据分析。我们的荟萃分析最终共纳入八项研究。我们的主要分析发现,与对照组相比,卡介苗接种组的SARS-CoV-2感染率显著降低,优势比为0.61,(95%置信区间为0.39至0.95,P = 0.03;I² = 31%,P = 0.21)。我们的研究表明,卡介苗接种可以预防SARS-CoV-2感染。然而,没有足够的证据表明卡介苗接种可以降低COVID-19的严重程度。